219 related articles for article (PubMed ID: 32122923)
1. Genomic and Immunologic Characterization of INI1-Deficient Pediatric Cancers.
Forrest SJ; Al-Ibraheemi A; Doan D; Ward A; Clinton CM; Putra J; Pinches RS; Kadoch C; Chi SN; DuBois SG; Leavey PJ; LeBoeuf NR; Mullen E; Collins N; Church AJ; Janeway KA
Clin Cancer Res; 2020 Jun; 26(12):2882-2890. PubMed ID: 32122923
[TBL] [Abstract][Full Text] [Related]
2. SMARCB1/INI1-deficient sinonasal carcinoma shows methylation of RASSF1 gene: A clinicopathological, immunohistochemical and molecular genetic study of a recently described entity.
Laco J; Chmelařová M; Vošmiková H; Sieglová K; Bubancová I; Dundr P; Němejcová K; Michálek J; Čelakovský P; Mottl R; Sirák I; Vošmik M; Ryška A
Pathol Res Pract; 2017 Feb; 213(2):133-142. PubMed ID: 28069272
[TBL] [Abstract][Full Text] [Related]
3. Poorly differentiated chordoma with loss of SMARCB1/INI1 expression in pediatric patients: A report of two cases and review of the literature.
Cha YJ; Hong CK; Kim DS; Lee SK; Park HJ; Kim SH
Neuropathology; 2018 Feb; 38(1):47-53. PubMed ID: 28812319
[TBL] [Abstract][Full Text] [Related]
4. Tumor mutation burden, DNA mismatch repair status and checkpoint immunotherapy markers in primary and relapsed malignant rhabdoid tumors.
Abro B; Kaushal M; Chen L; Wu R; Dehner LP; Pfeifer JD; He M
Pathol Res Pract; 2019 Jun; 215(6):152395. PubMed ID: 31047727
[TBL] [Abstract][Full Text] [Related]
5. SMARCB1-deficient Tumors of Childhood: A Practical Guide.
Pawel BR
Pediatr Dev Pathol; 2018; 21(1):6-28. PubMed ID: 29280680
[TBL] [Abstract][Full Text] [Related]
6. Infrequent SMARCB1/INI1 gene alteration in epithelioid sarcoma: a useful tool in distinguishing epithelioid sarcoma from malignant rhabdoid tumor.
Kohashi K; Izumi T; Oda Y; Yamamoto H; Tamiya S; Taguchi T; Iwamoto Y; Hasegawa T; Tsuneyoshi M
Hum Pathol; 2009 Mar; 40(3):349-55. PubMed ID: 18973917
[TBL] [Abstract][Full Text] [Related]
7. [Pediatric SMARCB1/INI1-deficient poorly differentiated chordoma of the skull base: report of five cases and review of literature].
Duan ZJ; Yao K; Ma Z; Hu ZJ; Xiang L; Qi XL
Zhonghua Bing Li Xue Za Zhi; 2022 Jan; 51(1):33-38. PubMed ID: 34979751
[No Abstract] [Full Text] [Related]
8. Primary adult sellar SMARCB1/INI1-deficient tumor represents a subtype of atypical teratoid/rhabdoid tumor.
Duan Z; Yao K; Yang S; Qu Y; Ren M; Zhang Y; Fan T; Zhao H; Gao J; Feng J; Fan X; Qi X
Mod Pathol; 2022 Dec; 35(12):1910-1920. PubMed ID: 35804041
[TBL] [Abstract][Full Text] [Related]
9. SMARCB1/INI1-deficient tumors of adulthood.
Parker NA; Al-Obaidi A; Deutsch JM
F1000Res; 2020; 9():662. PubMed ID: 33796273
[TBL] [Abstract][Full Text] [Related]
10. Cytomorphologic Spectrum of SMARCB1-Deficient Soft Tissue Neoplasms.
Schaefer IM; Al-Ibraheemi A; Qian X
Am J Clin Pathol; 2021 Jul; 156(2):229-245. PubMed ID: 33608696
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic roles of SMARCB1/INI1 and its deficient tumors.
Kohashi K; Oda Y
Cancer Sci; 2017 Apr; 108(4):547-552. PubMed ID: 28109176
[TBL] [Abstract][Full Text] [Related]
12. SMARCB1/INI1 Involvement in Pediatric Chordoma: A Mutational and Immunohistochemical Analysis.
Antonelli M; Raso A; Mascelli S; Gessi M; Nozza P; Coli A; Gardiman MP; Arcella A; Massimino M; Buttarelli FR; Giangaspero F
Am J Surg Pathol; 2017 Jan; 41(1):56-61. PubMed ID: 27635948
[TBL] [Abstract][Full Text] [Related]
13. SMARCB1/INI1-deficient epithelioid and myxoid neoplasms in paratesticular region: Expanding the clinicopathologic and molecular spectrum.
Yin X; Yang X; Wang S; Zhou J; Zhao M
Ann Diagn Pathol; 2024 Feb; 68():152242. PubMed ID: 38039617
[TBL] [Abstract][Full Text] [Related]
14. Poorly differentiated chordoma showing loss of SMARCB1/INI1: Clinicopathological and radiological spectrum of nine cases, including uncommon features of a relatively under-recognized entity.
Rekhi B; Michal M; Ergen FB; Roy P; Puls F; Haugland HK; Soylemezoglu F; Kosemehmetoglu K
Ann Diagn Pathol; 2021 Dec; 55():151809. PubMed ID: 34482218
[TBL] [Abstract][Full Text] [Related]
15. Integrated genomics has identified a new AT/RT-like yet INI1-positive brain tumor subtype among primary pediatric embryonal tumors.
Ho DM; Shih CC; Liang ML; Tsai CY; Hsieh TH; Tsai CH; Lin SC; Chang TY; Chao ME; Wang HW; Wong TT
BMC Med Genomics; 2015 Jun; 8():32. PubMed ID: 26109171
[TBL] [Abstract][Full Text] [Related]
16. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
17. Highly aggressive behavior of malignant rhabdoid tumor: a special reference to SMARCB1/INI1 gene alterations using molecular genetic analysis including quantitative real-time PCR.
Kohashi K; Oda Y; Yamamoto H; Tamiya S; Izumi T; Ohta S; Taguchi T; Suita S; Tsuneyoshi M
J Cancer Res Clin Oncol; 2007 Nov; 133(11):817-24. PubMed ID: 17486366
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune-checkpoint inhibitor-related biomarkers.
Nazha B; Zhuang T; Wu S; Brown JT; Magee D; Carthon BC; Kucuk O; Nabhan C; Barata PC; Heath EI; Ryan CJ; McKay RR; Master VA; Bilen MA
Cancer; 2023 Dec; 129(24):3884-3893. PubMed ID: 37565840
[TBL] [Abstract][Full Text] [Related]
19. Pan-cancer landscape of
Huang RSP; Murugesan K; Montesion M; Pavlick DC; Mata DA; Hiemenz MC; Decker B; Frampton G; Albacker LA; Ross JS
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33972391
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical validation of INI1/SMARCB1 in a spectrum of musculoskeletal tumors: an experience at a Tertiary Cancer Referral Centre.
Rekhi B; Jambhekar NA
Pathol Res Pract; 2013 Dec; 209(12):758-66. PubMed ID: 24075062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
